Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Enzolinion Nov 15, 2019 11:46am
93 Views
Post# 30356862

Mr. Gary Leong was the CSO of Kalytera!!!!

Mr. Gary Leong was the CSO of Kalytera!!!!

Kalytera Announces Changes to Board of Directors

V.KLY 

SAN FRANCISCO and TEL AVIV, Israel, June 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced changes to the Company’s Board of Directors (the "Board"). Mr. Robin “Rob” Hutchison has joined the Board to fill the vacancy created by the resignation of Mr. Gary Leong, an independent director who also served on the Company’s Audit and Governance and Nominating Committees. Mr. Hutchison, who is an independent director, will also serve as a member of the Company’s Audit, Compensation and Governance and Nominating Committees.

“Rob brings a wealth of financial and business experience to Kalytera,” commented Ron Erickson, Chairman of the Board.  “Rob has significant expertise regarding intellectual property, patents, business valuations, and business management. We are very pleased that he has agreed to join our Board, and we look forward to his contributions as we continue to execute on our strategy in the years to come.” Mr. Erickson also stated that, “Gary Leong has made invaluable contributions to Kalytera during his tenure. On behalf of the Company, we are grateful for his service and dedication.”


Before posting lies read back!!!! 



Bullboard Posts